COMP <GO>
RS vs TMO // REVENUE GROWTH (YOY)
Reliance Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: RS 6
— TMO 8
▲ REVENUE GROWTH (YOY) LEADER: TMO
LAST: $436.91 (-0.64%) • MKT CAP: $22.40B
revenue-growth
3.30%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
revenue-growth
3.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RS VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RS | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.60% | 9.30% | +0.30 | RS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.3x | 30.4x | -12.10 | RS | /valuation <GO> |
| Free Cash Flow Yield | 2.24% | 2.40% | -0.16 | TMO | /fcf-yield <GO> |
| Operating Margin | 7.10% | 17.40% | -10.30 | TMO | /operating-margins <GO> |
| Net Profit Margin | 5.20% | 15.10% | -9.90 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 3.30% | 3.90% | -0.60 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.27 | 4.50 | +2.77 | RS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.70% | -0.20 | RS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.1 | 59.1 | +11.96 | RS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.94 | -0.05 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.2x | 36.3x | -8.10 | RS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.40B | $262.22B | -$239.82B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RS REV | TMO REV | RS GROSS % | TMO GROSS % | RS FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.29B | $44.56B | 44.0% | 44.0% | $502.5M | $6.29B |
| FY 2024 | $13.84B | $42.88B | 44.0% | 44.0% | $999.2M | $7.27B |
| FY 2023 | $14.81B | $42.86B | 44.0% | 44.0% | $1.01B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RS // BETA 0.89
TMO // BETA 0.94